Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin

Leukemia. 2010 Feb;24(2):467-9. doi: 10.1038/leu.2009.214. Epub 2009 Oct 22.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aminoglycosides / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use
  • Female
  • Gemtuzumab
  • Humans
  • Karyotyping
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Male
  • Middle Aged
  • Mutation / genetics
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / genetics
  • Nuclear Proteins / genetics*
  • Nucleophosmin
  • Prognosis
  • Salvage Therapy
  • Tandem Repeat Sequences
  • Treatment Outcome
  • Young Adult
  • fms-Like Tyrosine Kinase 3 / genetics*

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • NPM1 protein, human
  • Nuclear Proteins
  • Nucleophosmin
  • Gemtuzumab
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3